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ABSTRACT
Background The SafeBoosC phase II randomised
clinical trial recently demonstrated the beneﬁts of a
combination of cerebral regional tissue oxygen saturation
(rStO2) by near-infrared spectroscopy (NIRS) and a
treatment guideline to reduce the oxygen imbalance in
extremely preterm infants.
Aims To analyse rStO2-alarm-related clinical decisions
and their heterogeneity in the NIRS experimental group
(NIRS monitoring visible) and their impact on rStO2 and
SpO2.
Methods Continuous data from NIRS devices and the
alarms (area under the curve of the rStO2 out of range
had accumulated 0.2%h during 10 min), clinical data at
discrete time points and interventions prompted by the
alarms were recorded.
Results Sixty-seven infants had data that fulﬁlled the
requirements for this analysis. 1107 alarm episodes were
analysed. The alarm triggered a treatment guideline
intervention in 25% of the cases; the type of
intervention chosen varied among clinical sites. More
than 55% of alarms were not followed by an
intervention (‘No action’); additionally, in 5% of alarms
the rStO2 value apparently was considered non-reliable
and the sensor was repositioned. The percentage of
unresolved alarms at 30 min after ‘No action’ almost
doubled the treatment guideline intervention (p<0.001).
Changes in peripheral oxygen saturation (SpO2), were
observed only after treatment guideline interventions.
Conclusions This study shows that 25% of rStO2
alarms were followed by a clinical intervention
determined by the treatment guideline. However, the
rStO2 and SpO2 returned to normal ranges after the
intervention, supporting the notion that decisions taken
by the clinicians were appropriate.
Trial registration number ClinicalTrial.gov
NCT01590316.
INTRODUCTION
The SafeBoosC phase II randomised clinical trial
was a pragmatic medical device trial to obtain
evidence-based knowledge on the beneﬁts and
harms of cerebral monitoring using near-infrared
spectroscopy (NIRS) as a part of routine manage-
ment of premature infants.1 NIRS-derived absolute
regional cerebral tissue oxygen saturation (rStO2) is
a composite measure of tissue oxygen saturation
across arterial, capillary and venous beds and
reﬂects a balance between cerebral oxygen delivery
and consumption.2–5 The aim of the SafeBoosC
phase II randomised clinical trial was the stabilisa-
tion of cerebral oxygenation by the combined use
of rStO2 monitoring and an evidence-based treat-
ment guideline6 as a brain-oriented protection strat-
egy with the goal of reducing ﬂuctuations in
oxygen delivery and consumption.7–9
The treatment guideline was developed focusing
on interventions that could have an impact on
arterial oxygen saturation (SpO2), haemoglobin
concentration and cerebral blood ﬂow, which are
the main determinants of oxygen delivery to the
brain. This treatment guideline suggested potential
interventions to be considered by the physicians
within the range of the policies currently in place
in their units.6
The SafeBoosC phase II randomised clinical trial
demonstrated that cerebral oxygenation can be sta-
bilised in extremely preterm infants during the ﬁrst
3 days after birth with a median 58% reduction in
the burden of hypoxia and hyperoxia in the experi-
mental group in comparison with the control
group.1 The purpose of this report is to analyse the
trial-related clinical decisions and their impact on
Open Access
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What is already known on this topic
Cerebral hypoxia and hyperoxia of infants are
associated with adverse outcomes. A variety of
studies, mostly observational, have addressed the
effect of different interventions on brain
oxygenation using near-infrared spectroscopy
(NIRS). The beneﬁts of a combination of cerebral
NIRS and a dedicated treatment guideline to
reduce the amount of oxygen imbalance in the
brain have been recently reported (The SafeBoosC
randomised clinical trial).
What this study adds
This study reports on the SafeBoosC trial-related
clinical decisions and their impact on the infant’s
condition. In addition, this study reports about the
heterogeneity among participating centres,
possibly due to a variety of local clinical care
policies with a focus on the optimal design for a
large-scale conﬁrmatory trial.
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the infants’ condition (rStO2 and SpO2) as well as potential het-
erogeneity among the participating centres with a focus on the
optimal design for a large scale, multicentre trial with a patient-
relevant outcome.
METHODS
Design and study population
The trial included infants from eight different European coun-
tries. It was approved by each hospital’s local research ethics
committee, and, where required (Austria, Denmark, France, and
Switzerland), by the competent authority responsible for
medical devices. Details regarding the trial protocol, clinical
characteristics of infants and main outcomes have been reported
elsewhere.1 10 Recruitment was conducted between June 2012
and December 2013. Brieﬂy, infants of gestational age up to
27 weeks and 6 days, with the possibility to start cerebral NIRS
monitoring within 3 h after birth, who had written informed
consent, were considered eligible for the trial. By means of a
central web-based randomisation system infants were allocated
to either the experimental group, with the cerebral NIRS moni-
toring visible, or the control group with the cerebral NIRS mon-
itoring blinded.
Software analysing procedure and study workﬂow
In the experimental group the alarm was activated when the
area under the curve (AUC) of the rStO2 out of normal range,
deﬁned as rStO2 between 55% and 85%, had accumulated
0.2%h during the past 10 min.1 The units are expressed as %h
because the AUC is calculated from time (x-axis) and rStO2%
(y-axis).
Software was speciﬁcally developed to calculate the alarm.
The software received data from the NIRS device and calculated
the AUC and generated the alarm. The software also showed
trends in rStO2 and provided a recording system for interven-
tions related to the treatment guideline as well as a dataset
(physiological and biochemical variables and ventilator settings).
The data were manually entered into this software programme
by the clinical staff.
A dedicated treatment guideline was available to the clinical
staff listing possible interventions to normalise an out of range
rStO2.
6 The interventions were focused on respiratory and cir-
culatory support and are described in detail elsewhere.6 The
treatment guideline was in accordance with the current national
clinical practices. If an alarm prompted a clinical intervention
this was reported in the software from a drop down menu
listing various interventions. If a different intervention to that
listed in the treatment guidelines was implemented, it was docu-
mented as ‘Other’. If after careful evaluation, the attending staff
judged that there was no reason to believe that the infant was
compromised, then the decision was ‘No action’.6
A dataset was recorded every 6 h according to the protocol
and included heart rate, peripheral oxygen saturation (SpO2),
mean arterial blood pressure, mean airway pressure, inspired
oxygen fraction, and pH, blood gases, lactate, base excess,
haemoglobin and glycaemia if available. These data were also
requested at the start of the alarm and 30 min later (ﬁrst
review); in case the alarm was not resolved (AUC still above
0.2%h in the last 10 min) within the ﬁrst 30 min a second
review dataset was also requested 30 min after the ﬁrst review.
The bedside software programme displayed the quality of the
NIRS values provided by the device; this prevented missing
values and false readings that could lead to inappropriate inter-
ventions. The various cerebral oximeters used in the study were
comparable in terms of absolute value, repeatability and sensitiv-
ity to changes in oxygenation on the adult, human forearm.11 12
Local staff was trained as appropriate to supervise all partici-
pants during the intervention. To minimise skin irritation
related to the device it was recommended to move the NIRS
sensor to a different location at the skull as often as every 4 h to
avoid damage from heat and/or pressure. Each NIRS sensor
reposition was also documented.
Data analysis
Each site downloaded data to the data management centre after
completion of the participant’s intervention period. Using a
Matlab (MathWorks, Natick, Massachusetts, USA) script created
for this purpose, NIRS ﬁles, event ﬁles (decisions and sensor
reposition information) and dataset were preprocessed. Data
were reviewed manually to check data consistency.
Sensor reposition that occurred within the 10 min period fol-
lowing a previous sensor site reposition was considered a single
event. In addition, NIRS sensor repositioning occurring within
the 10 min period that followed an alarm in which the decision
taken was ‘No action’ was analysed separately; this was consid-
ered as an intervention that was termed ‘Alarm-prompted repos-
ition’. In these cases the alarm apparently was judged to be the
consequence of poor sensor–skin contact yielding to non-
reliable warning. Alarms occurring within the 15 min period
following sensor repositioning were discarded.
Statistics
The data were analysed using the statistical software SAS V.9.2
(Cary, North Carolina, USA). The quantitative data are given as
means (SD or 95% CI) or median (IQR) and the qualitative data
as counts and percentages. Mixed-model analysis was used to
adjust the effect of repeated measures per centre or total popu-
lation. To avoid the effect of variations in study duration among
infants results are expressed as ‘per time unit’.
In addition to rStO2, the peripheral SpO2 was chosen as the
physiological variable to evaluate the impact of warnings and
Table 1 Perinatal and neonatal data of the study population
Gestational age (w), mean (SD) 26.38 (1.18)
Birth weight (g), mean (SD) 854 (206)
Male, n (%) 36 (54)
Multiple, n (%) 13 (19)
Apgar score ≤5 at 5 min, n (%) 11 (16)
Antenatal steroids, n (%) 49 (73)
Chorioamnionitis, n (%) 6 (9)
Rupture of membranes, >24 h before labour n (%) 21 (31)
Surfactant administered*, n (%) 52 (78)
Mechanical ventilation*, n (%) 46 (69)
Treatment for patent ductus arteriosus*, n (%) 13 (19)
Necrotising enterocolitis†, n (%) 9 (13)
Retinopathy of prematurity‡, n (%) 12 (18)
Severe brain injury§, n (%) 9 (14)
Periventricular haemorrhagic infarction 6 (9)
Grade 3 intraventricular haemorrhage 2 (3)
Posthaemorrhagic ventricular dilatation 3 (4.6)
Lenticulostriatal stroke 1 (1.5)
Death before discharge, n (%) 7 (10)
*Refers to the intervention period (first 72 h from birth).
†Modified Bell’s stage 2 or 3.13
‡Stage 3 or worse on international classification.14
§Overall cranial ultrasound score reflecting the worst of the serial scans from birth to
discharge or death.
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eventual clinical decisions on the infants’ status. The peripheral
SpO2 value was calculated as the averaged mean value entered
at the time of the alarm and at 30 and 60 min of warning. The
rStO2 value was derived from the averaged mean of all samples
obtained during 1 min at the time datasets were entered. The
unresolved alarm by time according to type of decision taken by
clinicians was represented using the Kaplan and Meier method;
differences were assessed by means of the log-rank test.
RESULTS
Among the 86 infants included in the SafeBoosC trial in the
NIRS experimental group,1 67 (78%) had data that fulﬁlled the
requirements for this analysis. The remaining 19 infants were
excluded due to inappropriate use of the study software. Infants
were recruited in eight different centres, with a variable number
of infants in the experimental group per centre (ranging from 2
to 18). The mean duration of NIRS recordings during the inter-
vention period was 70.24 (SD 9.22) hours without differences
between centres. The clinical characteristics of the study popula-
tion are detailed in table 1.
Periodical repositioning per protocol of the NIRS sensor, as
suggested in the protocol, varied according to centre
(p<0.001), with a median of 0.18 (IQR 0.19) repositions
per hour (ranges 0.0–0.28). No differences in sensor reposition
according to NIRS device were found.
A total of 1107 alarm episodes (cerebral hypoxia, 874; cere-
bral hyperoxia, 233) were analysed from the 67 infants. The
decision taken in relation to alarm varied according to centre
(p=0.001) (table 2). The alarm triggered a treatment guideline
intervention in 25% of the total alarm episodes (ﬁgure 1). In
most treatment guideline interventions the choice was a change
in FiO2, consisting of an increase in FiO2 in 177 (88.1%) epi-
sodes and a decrease in FiO2 in 24 (11.9%) episodes.
Statistically signiﬁcant differences were found among centres
in relation to the type of intervention chosen (p=0.001).
Centres 1, 2, 4, 6 and 7 were more prone to FiO2 adjustment,
whereas centres 3 and 5 chose more often a different balance
between FiO2 and ventilator settings. The time needed for the
alarm to resolve varied according to type of decision taken
(p<0.001) (ﬁgure 2).
We explored the impact of the decision taken on SpO2. The
averaged mean SpO2 at start of the alarm warning was 90.0%
(SD 9.6), while it was 92.4% (SD 6.8) at the ﬁrst (30 min) and
92.9% (SD 6.7) at the second (60 min) review. However, the
proﬁle of SpO2 and rStO2 changes showed differences accord-
ing to the decisions taken in response to alarm (ﬁgure 3).
Higher FiO2 was associated with lower rStO2 (p=0.057) and
Table 2 Decision taken by clinicians in response to alarm per centre
Centre
Alarm/h
per patient
(95% CI)
Treatment guideline intervention
No action, n (%) Other, n (%)
Alarm-prompted
reposition, n (%)Total n (%) FiO2 adjustment n (%)*
1 0.32 (0.07 to 0.55) 38 (24) 35 (92) 100 (63) 16 (10) 5 (3)
2 0.39 (0.22 to 0.56) 78 (22) 65 (83) 196 (56) 66 (19) 13 (4)
3 0.09 (0.06 to 0.11) 30 (26) 9 (30) 33 (29) 26 (23) 26 (23)
4 0.16 (0.06 to 0.27) 31 (42) 27 (87) 38 (52) 4 (5) 0 (0)
5 0.19 (0.12 to 0.28) 40 (22) 15 (37) 115 (65) 20 (11) 3 (2)
6 0.33 (0.02 to 0.58) 18 (19) 16 (89) 57 (61) 16 (17) 2 (2)
7 0.24 (0.01 to 0.46) 37 (37) 32 (86) 49 (49) 9 (9) 4 (4)
8 0.32 (0.12 to 0.90) 4 (11) 2 (50) 27 (73) 2 (5) 4 (11)
Total 0.23 (0.18 to 0.29) 276 (25) 201 (73) 615 (56) 159 (14) 57 (5)
*FiO2 adjustment expressed as percentage within the treatment guideline interventions.
Figure 1 Flow diagram describing
the potential decisions offered in
response to an alarm and the
distribution of choices according to the
clinical staff preference. PDA, patent
ductus arteriosus.
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SpO2 (p<0.001). Table 3 shows rStO2 and SpO2 according to
the level of supplemental oxygen at the time of dataset.
DISCUSSION
This report focuses on the alarm episodes analyses and the deci-
sions taken in the experimental group (visible NIRS) of the
SafeBoosC phase II randomised clinical trial. The alarm warned
the clinical staff of situations where the brain could be exposed
to hypoxia or hyperoxia, and potential clinical interventions
were suggested in a treatment guideline6 to normalise an out of
range rStO2. However, more than 55% of the warning episodes
were not followed by an intervention. Two important aspects
need to be considered. First, the infants in the study were moni-
tored by other devices apart from NIRS and only the interven-
tions triggered by NIRS warnings were recorded in the
SafeBoosC phase II trial software. Second, the NIRS alarm accu-
mulated the values of rStO2 obtained over the preceding
10 min, while the other monitoring systems did not (real-time
reading and immediate alert system). These facts raise two
important limitations of the present study. On the one hand, if
compromised cerebral perfusion–oxygenation was suspected,
successful treatment interventions may have been driven by
other monitoring devices, such as transcutaneous blood gas
monitoring, pulse oximetry or others, and been implemented
before the NIRS alarm warned the clinicians (not enough time
to accumulate an out of range rStO2). On the other hand, if the
intervention triggered by other devices was not rapidly effective
and the infant’s impaired condition was maintained for a longer
period, the accumulated out of range rStO2 would have trig-
gered an alarm; in this case, the clinician eventually might have
decided not to take any further action because appropriate
action had already been implemented some minutes earlier. This
may falsely inﬂate the ‘No action’ response. As there is no alter-
native monitoring system for the continuous assessment of brain
oxygenation the possibility to address these issues is limited. We
would like to remark that evidence supporting the treatment
guideline interventions is relatively low and cannot be recom-
mended outside a research setting.
The time needed for the alarm to be resolved varied accord-
ing to the type of the decision taken (ﬁgure 2). Sensor reposi-
tioning (‘Alarm-prompted reposition’) returned rStO2 to normal
values (55%–85%) within 30min in 80% of alarms and within
100 min in all alarms. The percentage of alarms not resolved at
30 and 60 min after ‘No action’ were almost double compared
with those in which there was an intervention (‘Treatment
guideline intervention’). Yet, despite an intervention, 15% of
these were unresolved by 60 min. This means that even if the
intervention chosen was appropriate, the mechanism involved in
improving brain perfusion–oxygenation takes more time to be
fully resolved. Finally, in some very ill infants, it is likely that
cerebral hypoxia has been resistant to all interventions. It is
important to note, however, that data collection may have
varied both within and between centres. As it was manually
entered, some interventions may not have been properly docu-
mented. Furthermore, the 30 and 60 min points are likely to be
insufﬁcient to catch the details of multiple interventions. In the
design of the study we chose those to avoid overloading the
clinical staff with registration and thereby compromising the
primary purpose of the trial.
To further evaluate the impact of alarms and decisions we
analysed the evolution of SpO2 and rStO2 at the time of the
alarm and the subsequent reviews according to the type of deci-
sion taken by the clinician. As illustrated in ﬁgure 3, when the
decision was a ‘Treatment guideline intervention’ the averaged
mean SpO2 showed the greatest change, from the lowest mean
value at start of warning to a more physiological and stable post-
warning average value at ﬁrst (30 min) and second (60 min)
reviews. Interestingly, when the decision was ‘No action’, the
averaged mean SpO2 did not signiﬁcantly vary, and remained
during the whole intervention period within ‘acceptable’ clinical
ranges. More obviously, repositioning the NIRS sensor did not
change SpO2. Thus, trends in SpO2 support the contention that
the decisions taken by clinicians were appropriate in most cases.
As the average SpO2 at the time of the rStO2 alarm was as low
as 85%, it is not a surprise that the most common intervention
was to increase FiO2. It is more of a surprise that the FiO2 was
not increased before the rStO2 alarm as most units target SpO2
at 90%–95%.
We found a negative association between FiO2 and both
rStO2 and SpO2. By stratifying the group into (a) infants in
room air, (b) infants on low supplementary oxygen (22%–29%)
and (c) infants on high oxygen supplementation (>29%), we
found that the impact of FiO2 on rStO2 and SpO2 differed. The
healthier the infant was (and so, the lower the supplementary
Figure 2 Kaplan–Meier plot diagram
representing the time needed for the
alarm to be resolved according to type
of decision taken (differences between
‘No action’ and ‘Treatment guideline
intervention’ (p<0.001);
‘Alarm-prompted reposition’
(p=0.001); ‘Other’ (p=0.009)).
Unresolved alarms, percentage of
alarms that remain active.
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oxygen needs) the higher the associated rStO2 and SpO2 values
were (table 3). This also supports the notion that other treat-
ment strategies suggested by the treatment guidelines, apart
from FiO2 adjustment, contributed to the return of rStO2 to
normal ranges, particularly in the sickest infants.
In our experience, the rStO2 alarm deﬁned in this study
protocol was rarely used to initiate treatment of a patent ductus
arteriosus or guiding glucose intake. The former is more
dependent on the variations in neonatal intensive care unit pol-
icies with regards to early echocardiographic assessment in these
infants.
We observed wide differences in sensor repositioning among
the participating centres. This difference was not explained by
the brand of NIRS device used but possibly by differences in
sensor ﬁxation, registration of repositioning or compliance with
the standard operating procedure among centres.
On average four interventions for infants in the experimental
group achieved the 58% reduction in the AUC of hyperoxia and
hypoxia that we previously reported.1 As previously stated our
data collection was not perfect and an in-depth analysis of the
complex interaction of cerebral NIRS and the already available
monitoring systems is difﬁcult. From the results presented here
it seems that cerebral NIRS monitoring did add some informa-
tion that resulted in additional interventions. This was expected.
Treatment was not changed in 75% of alarms. This may seem
high, but it would on the other hand be surprising if out of
range NIRS always resulted in interventions in such complex
clinical scenarios as presented by this study population.
Whether the NIRS monitoring also hindered some interventions
is uncertain. Finally, we observed heterogeneity in the number
of alarms between centres. We speculate this could be due to
differences in clinical staff training on NIRS monitoring among
the study participants1 and in the severity of infant conditions.
The patient-relevant clinical beneﬁt of this complex intervention
remains to be determined.
The absolute values provided by cerebral NIRS have shown
poor repeatability and differences between the varied
devices.15 16 To deal with this, systematic pretrial testing was
conducted using several NIRS instruments.11 17 Only two NIRS
devices were used in this study reducing heterogeneity. We have
to depend on the absolute values of cerebral tissue oxygenation
and on absolute thresholds for intervention.
CONCLUSIONS
This post hoc analysis of the alarm episodes and their subse-
quent management in the experimental group of the SafeBoosC
II randomised clinical trial revealed that three quarters of all
alarms triggered were not followed by an active intervention at
the bedside, suggesting that the treating clinician was content
with the infant’s overall status despite a cerebral oxygen outside
Figure 3 Impact of type of decision taken in response to alarm
episodes on the rStO2 and the peripheral oxygen saturation (SpO2)
used as a physiological proxy of cerebral oxygen saturation (rStO2).
The rStO2 (hypoxia, (A); hyperoxia, (B)) and SpO2 (C) averaged means
(95% CI) at onset of the alarm and at ﬁrst (30 min) and second
(60 min) review are represented.
Table 3 Cerebral (rStO2) and peripheral (SpO2) oxygen saturation
according to level of inspired supplemental oxygen (FiO2)
FiO2 value (%) rStO2% (SD) (n) SpO2% (SD) (n)
21 64.9 (15.9) (580) 94.5 (5.2) (711)*
22–29 67.3 (14.8) (376)† 92.8 (4.6) (447)
≥30 63.8 (11.8) (149)† 92.0 (4.1) (180)
*Differences between 21% and the other two FiO2 strata (p<0.001).
†Differences between 21% and 22%–29% FiO2 strata (p=0.001).
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of the monitoring range. However, 25% of the alarms triggered
a treatment guideline intervention, averaging four interventions
per infant, supporting the strength of this non-invasive monitor-
ing system. Limitations of the study design, however, restrict the
generalisability of the results. For a large-scale trial of monitor-
ing of cerebral oxygenation with patient-relevant outcomes
study staff must be adequately trained in the application of
NIRS and the pathophysiological basis for the choice of
intervention.
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